Clinical trials: Relative Bioavailability
Epilepsy
A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)
This multi-center, two-treatment study compares the pharmacokinetic profiles of Immediate Release (IR) and Modified Release (MR) formulations of Topiramate (TPM) in patients with epilepsy.
- Trial name
- NCT01114854
- Testing
- Topiramate IR, Topiramate ER
- Where
- 9 sites in United States
- Volunteers
- 69 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Healthy
Finasteride 5 mg Tablets Under Fasting Conditions
The objective of this study is to compare the relative bioavailability of finasteride 5 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of PROSCAR® 5 mg tablets (Merck) in healthy, adult…
- Trial name
- NCT00835666
- Testing
- Finasteride 5 mg tablets, PROSCAR®
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
Relative Drug Exposures Of Two Formulations of PF-02341066
The study will be an open-label, randomized, 2-period, 2-treatment, 2-sequence, cross-over, single-dose study employing administration of two PF-02341066 formulations in the fasted state to healthy adult volunteers.
- Trial name
- NCT00939731
- Testing
- PF-02341066
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetics and relative bioavailability of 4 new formulations of fentanyl transdermal patch in healthy participants after a single application for 72 hours.
- Trial name
- NCT01717157
- Testing
- Treatment A: DUROGESIC (8.4 mg fentanyl), Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl), Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)
- Where
- Belgium
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects
Comparative pharmacokinetics of 2-4 experimental modified release formulations and oral solution of BIBV 308 SE following multiple doses, tolerability
- Trial name
- NCT02223000
- Testing
- BIBV 308 SE solution, BIBV 308 SE capsule 1, BIBV 308 SE capsule 2
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis, Relapsing-Remitting
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
GSK2018682 is a potent and selective agonist for the sphingosine-1- phosphate receptor subtype 1 (S1P1) with the potential to be an effective treatment for multiple sclerosis (MS).
- Trial name
- P1A114919 (NCT01466322)
- Testing
- GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma With Eosinophilic Phenotype
A Study Comparing a Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants
This is a single-center, randomized, parallel-group, open-label clinical study designed to compare the bioavailability and safety of SHR-1703 Injection administered subcutaneously using a pre-filled safety syringe (PFS) or a…
- Trial name
- NCT07701239
- Testing
- SHR-1703 Injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Healthy
A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)
The purpose of this study is to learn what happens to the amount of enlicitide decanoate in the blood when enlicitide decanoate is given in different formulations.
- Trial name
- NCT06691906
- Testing
- Enlicitide decanoate
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Subjects
To Study And Compare Bioavailability And Safety Of Four Different Formulations Of The Study Drug
SB-742510 is a semi-synthetic pleuromutilin antibiotic that is being developed for treatment of respiratory infections. The purpose of this study is to estimate the bioavailability of four different formulations and to evaluate…
- Trial name
- NCT00436228
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Participants
A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers
This study will assess the pharmacokinetics of AZD5462 film-coated tablet formulation in healthy participants.
- Trial name
- NCT05512806
- Testing
- AZD5462
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181
To investigate the safety, tolerability, pharmacokinetics (including dose proportionality assessment), and pharmacodynamics of single rising oral doses of BI 1181181 (Single rising dose (SRD) part) Secondly, to investigate the…
- Trial name
- NCT02044406
- Testing
- BI 1181181, BI 1181181, R, BI 1181181, T2
- Where
- Germany
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study of LY3337641 in Healthy Participants
The purposes of this study are to determine: If there are any differences in the amount of LY3337641 in the blood/body when it is taken in different formulations. A total of 3 different formulations of LY3337641 are being tested.
- Trial name
- NCT03099148
- Testing
- Reference Formulation (R), LY3337641 (T1), LY3337641 (T2)
- Where
- 2 sites in Singapore
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Relative Bioavailability Study of Acetaminophen 650 mg Extended Release Gelcaps Under Fed Condition
The study was conducted as an open label, balanced, randomised, two-treatment, two-period, two-sequence, single dose, crossover bioavailability study comparing acetaminophen extended release gelcaps 650 mg (containing…
- Trial name
- NCT01079078
- Testing
- Acetaminophen
- Where
- India
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Inflammatory Diseases
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.
The purpose of the study is to assess the safety and tolerability of AZD6793 suspension following oral administration of Single Ascending Dose (SAD) [Part 1] and Multiple Ascending Dose (MAD) [Part 2] in healthy participants.
- Trial name
- NCT05662033
- Testing
- AZD6793
- Where
- 2 sites in United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions
The purpose of this study is compare the relative bioavailability of 750 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co with that of 750 mg GLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company…
- Trial name
- NCT00865852
- Testing
- Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Melanoma, BRAF V600 Mutation
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
The current commercially available MEKTOVI® (binimetinib) 15 mg tablets are provided as immediate release film-coated tablets for oral administration.
- Conditions
- Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
- Trial name
- NCT05103891
- Testing
- Binimetinib Oral Tablet
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Healthy
Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation
This study will assess the relative bioavailability of a capsule formulation of PF-04958242, relative to a oral solution formulation of PF-04958242 in healthy adult subjects.
- Trial name
- NCT01646840
- Testing
- PF-04958242 capsule, PF-04958242 oral solution
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy Volunteers
A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants
The purpose of this study is to assess the oral BA of TAK-831 T3 tablet formulation relative to TAK-831 T2 tablet formulation under fasting conditions and to assess the effect of food on the pharmacokinetics (PK) of TAK-831 T3…
- Trial name
- NCT03706469
- Testing
- TAK-831 T2, TAK-831 T3
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Healthy Volunteers
A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants
The purpose of this study is to assess the relative bioavailability of a TAK-648 tablet compared with a TAK-648 oral solution, and to assess the effect of food on the bioavailability of a TAK-648 tablet in healthy participants.
- Trial name
- NCT02480439
- Testing
- TAK-648 Tablet, TAK-648 Oral Solution
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Volunteer
Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib
to evaluate the effect of the PPI (rabeprazole) on the PK of a potential commercial tablet formulation of palbociclib
- Trial name
- NCT03220191
- Testing
- Palbociclib, Rabeprazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer